Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
- SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
- “The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
- “The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects.
- In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated.